Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera’s key metabolite Withaferin A
© Saha et al.; licensee Springer. 2013
Received: 22 May 2013
Accepted: 24 July 2013
Published: 29 July 2013
Angiogenesis, or new blood vessel formation from existing one, plays both beneficial and detrimental roles in living organisms in different aspects. Vascular endothelial growth factor (VEGF), a signal protein, well established as key regulator of vasculogenesis and angiogenesis. VEGF ensures oxygen supply to the tissues when blood supply is not adequate, or tissue environment is in hypoxic condition. Limited expression of VEGF is necessary, but if it is over expressed, then it can lead to serious disease like cancer. Cancers that have ability to express VEGF are more efficient to grow and metastasize because solid cancers cannot grow larger than a limited size without adequate blood and oxygen supply. Anti-VEGF drugs are already available in the market to control angiogenesis, but they are often associated with severe side-effects like fetal bleeding and proteinuria in the large number of patients. To avoid such side-effects, new insight is required to find potential compounds as anti-VEGF from natural sources. In the present investigation, molecular docking studies were carried out to find the potentiality of Withaferin A, a key metabolite of Withania somnifera, as an inhibitor of VEGF.
Molecular Docking studies were performed in DockingServer and SwissDock. Bevacizumab, a commercial anti-VEGF drug, was used as reference to compare the activity of Withaferin A. X-ray crystallographic structure of VEGF, was retrieved from Protein Data Bank (PDB), and used as drug target protein. Structure of Withaferin A and Bevacizumab was obtained from PubChem and ZINC databases. Molecular visualization was performed using UCSF Chimera.
Withaferin A showed favorable binding with VEGF with low binding energy in comparison to Bevacizumab. Molecular Docking studies also revealed potential protein-ligand interactions for both Withaferin A and Bevacizumab.
Conclusively our results strongly suggest that Withaferin A is a potent anti-VEGF agent as ascertained by its potential interaction with VEGF. This scientific hypothesis might provide a better insight to control angiogenesis as well as to control solid cancer growth and metastasis.
KeywordsAngiogenesis VEGF Withaferin A Withania somnifera Bevacizumab DockingServer SwissDock Chimera
Angiogenesis is a complex process, where angiogenic endothelial cells undergo a complex process that includes the secretion of metallo-proteases, cell migration, endothelial cell division, and proliferation, including the new blood vessel formation from the endothelium of a pre-existing vasculature (Bruick and McKnight 2001; Cébe-Suarez et al. 2006). Angiogenesis is involved in pathogenesis of various disorders like age-related macular degeneration, proliferative retinopathies, psoriasis, rheumatoid arthritis, and also most the common fatal disorder, solid cancer (Ruggeri et al. 2003; Folkman 1995; Ferrara 2001; Garner 1994). Angiogenesis can be controlled through different anti-angiogenic and pro-angiogenic factors (Drevs et al. 2004; Petrova et al. 1999). Controlling angiogenesis, we can ensure limited growth of solid cancer, because cancer cell will starve without extra supply of nutrients and oxygen (Folkman 1995; Ferrara 20022004).
Vascular endothelial growth factor (VEGF) is considered as one of the most vital pro-angiogenic factors involved in tumor angiogenesis (Ferrara 2001; Drevs et al. 2004; Ferrara et al. 2003). VEGF family comprising of glycoproteins designated as VEGF-A, VEGF-B,VEGF-C, VEGF-D, VEGF-E, placental growth factor (PGF), and VEGF-F are involved in the regulation of angiogenesis (Ball et al. 2007; Lee et al. 2010; Otrock et al. 2007; Fayette and Soria 2005).
The endothelial cells are considered to be a novel target for the therapies against cancer cells because of their genomic instability (Frumovitz and Sood 2007; Sood et al. 2011). VEGF is secreted from stabilized over expressed tumor cells, and binds to the receptors on the endothelial cells of existing blood vessels, ultimately leads to new blood vessels formation from existing one, which ensures extra nutrient and blood supply for tumor cell survival, proliferation, and metastasis (Terman and Stoletov 2001). To control angiogenesis, anti-VEGF agents and other VEGF inhibitors are being prescribed in combination with chemotherapy all over the world (Ferrara et al. 2005; Bender and Yamashiro 2011; Morabito and Maio 2006; Carter 2000). The anti-VEGF monoclonal antibody, Bevacizumab, is usually prescribed for the treatment of malignant cell (Ferrara et al. 2005; Bossung and Harbeck 2010). Bevacizumab is used not only in angiogenesis but also in the treatment of breast, colorectal, and prostate cancer (Ferrara et al. 2005; Boige and Malka 2005; Kluetz et al. 2010). But Bevacizumab therapy is associated with serious life threatening side-effects like proteinuria and fetal bleeding, at least in 38% patients (Frumovitz and Sood 2007).
Thus, natural bioactive compounds can be a better way to find new potential anti-VEGF agents with less side-effect to control angiogenesis. In this perspective, in the present in silico pharmacological investigation, Withania somnifera’s key metabolite Withaferin A, was studied for their inhibitory activity on VEGF. Different parameters like FullFitness, Gibbs free energy (ΔG), free energy of binding, inhibition constant (Ki), total energy of Van der Waals (vdW) force + hydrogen bond (Hbond) +desolv energy (EVHD), electrostatic energy, total intermolecular energy, frequency of binding, interact surface area. Ligand bond, non-ligand bond, hydrogen bond, and its length were studied. A complete interaction profile (hydrogen bonds, polar, hydrophobic, pi-pi, cation-pi and others), and hydrogen bonding interactions (HB plot) were also studied.
Ligand and receptor
Molecular docking using DockingServer
Molecular Docking calculations were undertaken using DockingServer (http://www.dockingserver.com) (Bikadi and Hazai 2009). DockingServer is a web-based interface to handle all aspects of molecular docking using AutoDock tools. It can be used for molecular docking and as well as for analysis of results. Moreover, protein and ligand structure can be inputted directly from databases. It has integrated some chemistry software to calculate different parameters of docking study in more efficient way. It was selected because it permits robust molecular docking in more user friendly way with high efficiency.
The MMFF94 force field (Halgren 1996a) was used for the energy minimization of ligand molecules (Withaferin A and Bevacizumab) using DockingServer. Gasteiger charge calculation method was utilized and partial charges were added to the ligand atoms. Non-polar hydrogen atoms were merged, and as well as rotatable bonds were defined.
Molecular Docking calculations were carried out on Withaferin A/ Bevacizumab-VEGF protein model. Necessary hydrogen atoms and solvation parameters were added to the structure with the help of AutoDock tools (Morris et al. 1998). Affinity (grid) maps of 40×40×40 Å (x, y, and z) grid points, and 0.375 Å spacing were automatically generated using the AutoGrid program (Morris et al. 1998). Box center was x: 0.38 Å, y: -2.98 Å and z: 20.51 Å.
Parameter set- and distance-dependent dielectric functions of AutoDock were used for calculating van der Waals and the electrostatic forces, respectively in the Molecular Docking studies.
Molecular Docking simulations were carried out utilizing the Lamarckian genetic algorithm (LGA), and the Solis & Wets local search method (Solis and Wets 1981). Initial position, orientation, and torsions of the ligand molecules (Withaferin A and Bevacizumab) were set on randomly basis. Each docking experiment was derived from 10 different consecutive runs that were set to terminate automatically after a maximum of 250000 energy evaluations. The population size of the docking was set to 150. During the search, a translational step of 0.2 Å, and quaternion and torsion steps of 5 were applied in the current docking.
Molecular docking using SwissDock
Molecular Docking calculations were performed using SwissDock (http://swissdock.vital-it.ch/) web service based on the docking software EADock DSS (Grosdidier et al. 2011a). This web-based service was selected because it has user friendly interface with the facility to input desired protein and ligand structures directly from databases, modify docking parameters, and visualize most favorable clusters online. Moreover, results can be downloaded and viewed in UCSF Chimera package.
A grid (Box size: 40×40×40 Å and box center: 0.38×-2.98×20.51 for x,y, and z, respectively) was designed in which many binding modes were generated for the most favorable bindings. Simultaneously, their CHARMM energies are estimated on the grid (Grosdidier et al. 2011b). Docking type was accurate and rigid. Each docking experiment was derived from 250 different consecutive runs. The binding modes with the most favorable energies were evaluated with Fast analytical continuum treatment of solvation (FACTS), and clustered. Binding modes were scored using their FullFitness and clustered. Clusters were then ranked according to the average FullFitness of their elements (Grosdidier et al. 2007). Results of the SwissDock were visualized by UCSF Chimera package (Pettersen et al. 2004).
Results and discussion
Ligand-protein interaction parameters by DockingServer
Free energy of binding (kcal/mol)
Inhibition constant, Ki (uM)
vdW + Hbond + desolv energy (EVHD) (kcal/mol)
Electrostatic energy (kcal/mol)
Total intermolec. energy (kcal/mol)
Decomposed interaction energies in kcal/mol by DockingServer
Cys 61 (0)
Thr 31 (-0.4238), Ser 50 (-0.1325), Glu 64 (0)
Cys 51 (-0.1675), Cys 60 (0)
Leu 32 (-0.1934), Glu 67 (0), Ile 29 (0), Lys 107 (0)
Glu 64 (-1.0692); Asp 34 (0)
Phe 36 (0)
Phe 47 (0); Ser 50 (0)
Clustering results obtained from the docking of Withaferin A into VEGF by SwissDock
No. of SwissDock clusters
Estimated ΔG (kcal/mol)
Clustering results obtained from the docking of Bevacizumab into VEGF by SwissDock
No. of SwissDock clusters
Estimated ΔG (kcal/mol)
Based on the results of docking studies, it has been clearly expressed that Withaferin A showed favorable binding with VEGF, and the results were highly comparable with the commercially available drug Bevacizumab. VEGF, as an angiogenic protein stimulates the process of angiogenesis through chemical stimulation. Withaferin A shows favorable binding with VEGF, which can be potential way to prevent chemical stimulation of VEGF to induce angiogenesis process in hypoxic condition of the solid tumors. Moreover, VEGF is considered as one of the most vital pro-angiogenic factors involved in tumor angiogenesis (Moreira et al., 2007). VEGF increases vascular permeability which propagates tumor dissemination with the supply of sufficient oxygen and nutrients (Moreira et al., 2007). Inhibition of VEGF can prevent aggressive tumor angiogenesis which prevents the supply of oxygen and nutrients, necessary for propagation of tumor; ultimate outcome is the retardation of tumor growth.
In hypoxic condition, up-regulation of hypoxia inducible factor (HIF1), provokes VEGF growth factor, which in association with other cytokines, induces neovascularization of tumors and creates favorable conditions to grow beyond the size limitation (Martinez et al., 2003). For the first time, VEGF was accused in angiogenesis when it was identified as a growth factor secreted by solid tumor cells, which caused the hyperpermeability of normal blood vessels (Senger et al., 1983). Though VEGF presents in almost every type of tumor, but it is high in concentration in the tumor blood vessels and hypoxic area of the tumor. VEGF binds with specific receptor, so inhibition of VEGF receptor or inhibition of VEGF to bind with the receptor can definitely retard the growth of solid tumors (Millauer et al., 1996). It has already been experimented that the injection of an antibody VEGF, suppresses the growth of solid tumors of human fibrosarcoma cell line HT-1080 (Asano et al., 1995).
Recently, in cancer therapy, new strategies show the clinical relevance of inhibiting VEGF when the angiogenesis process is exaggerated, particularly in pathological angiogenesis (Olsson et al., 2006). However, such therapies in the long term management of cancer can hamper the survival of blood vessels in the healthy tissues (Olsson et al., 2006). So, in the development of the inhibitor of VEGF, it is vital to preserve the pathways associated with the survival of blood vessels necessary to conduct normal physiological function and development (Olsson et al., 2006). In addition, VEGF is essential for transporting oxygen, nutrients, and the removal of carbon dioxide and metabolic end products from cells, tissues, and organs to accomplish normal physiological phenomena (Cines et al., 1998). In tumor therapy, while using VEGF inhibitor, we have to calculate risk benefit ratio to validate the therapy.
Throughout the study, Withaferin A was better VEGF inhibitor than Bevacizumab in aspect of binding and affinity. Clinically, Bevacizumab is the most successful VEGF-neutralizing agent which was approved by the United States Food and Drug Administration (FDA) in the year of 2004 (Olsson et al., 2006). In combination with chemotherapy, Bevacizumab prolongs the survival rate of patients with solid tumor (Olsson et al., 2006). It has been often regarded that anti-VEGF drugs normalize the tumor blood vessels, which ensures more efficient delivery of the chemotherapy drugs in the tissue (Jain 2005). In addition, another anti-VEGF drug, Ranibizumab, derived from the same mouse antibody as Bevacizumab, playing their role in controlling angiogenesis through the inhibition of a number of subtypes of VEGF (Haberfeld 2009). Withaferin A showed more promising activity than Bevacizumab in molecular docking studies which leads the potential of Withaferin A, as a promising VEGF inhibitor with lower side-effects because of its natural origin. Though only VEGF inhibition can’t inhibit tumor angiogenesis because there are many other endogenous anti-angiogenic factors available in our physiological system, but it can definitely retard aggressiveness of the tumor angiogenesis in some extent (Roskoski 2007).
The protein-ligand interaction studies play a vital role in the structure based drug design in dry lab. VEGF is one of the most attractive topics in cancer biology, biochemistry, and pharmacology, and in the recent years the number of studies focusing on its inhibition has increased manifolds. Present study, has given a new insight to inhibit VEGF with the key metabolite, Withaferin A of Withania somnifera. Further investigations like QSAR studies are required to study semi-synthetic derivatives of Withaferin A to get more favorable interaction into VEGF.
Chemistry at HARvard macromolecular mechanics
Fast analytical continuum treatment of salvation
Gibbs free energy
Hypoxia inducible factor
Lamarckian genetic algorithm
Merck molecular force field 94
Optimized potentials for liquid simulations
Protein data bank
Placental growth factor
University of California, San Francisco
Vascular endothelial growth factor
van der Waals.
We acknowledge the support of the Centre for Natural Products and Drugs (CENAR), university of Malaya, where Jamil A Shilpi is working as a BrightSparks postdoctoral fellow. We authors are also grateful to the developers of DockingServer, SwissDock, UCSF Chimera for providing excellent software facilities to carry out the present in silico pharmacology study.
- Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H: Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 1995, 55: 5296–5301.PubMedGoogle Scholar
- Ball SG, Shuttleworth CA, Kielty CM: Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007, 177: 489–500. 10.1083/jcb.200608093PubMed CentralView ArticlePubMedGoogle Scholar
- Bender GJ, Yamashiro DJ: Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist 2011, 16: 1614–1625. 10.1634/theoncologist.2011-0148View ArticleGoogle Scholar
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The protein data bank. Nucleic Acids Res 2000, 28: 235–242. 10.1093/nar/28.1.235PubMed CentralView ArticlePubMedGoogle Scholar
- Bikadi Z, Hazai E: Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform 2009, 1: 15. 10.1186/1758-2946-1-15PubMed CentralView ArticlePubMedGoogle Scholar
- Bikadi Z, Demko L, Hazai E: Functional and structural characterization of a protein based on analysis of its hydrogen bonding network by hydrogen bonding plot. Arch Biochem Biophys 2007, 461: 225–234. 10.1016/j.abb.2007.02.020View ArticlePubMedGoogle Scholar
- Boige V, Malka D: Therapeutic strategies using VEGF inhibitors in colorectal cancer. Bull Cancer 2005, 92: 29–36.Google Scholar
- Bolton E, Wang Y, Thiessen PA, Bryant SH: PubChem: Integrated Platform of Small Molecules and Biological Activities. Chapter 12. In Annual Reports in Computational Chemistry, Volume 4. Washington, DC: American Chemical Society; 2008.Google Scholar
- Bossung V, Harbeck N: Angiogenesis inhibitors in the management of breast cancer. Current Opin Obstet Gynecol 2010, 22: 79–86. 10.1097/GCO.0b013e328334e462View ArticleGoogle Scholar
- Bruick RK, McKnight SL: Building better vasculature. Genes Dev 2001, 15: 2497–2502. 10.1101/gad.931601View ArticlePubMedGoogle Scholar
- Carter SK: Clinical strategy for the development of angiogenesis inhibitors. Oncologist 2000, 5: 51–54. 10.1634/theoncologist.5-suppl_1-51View ArticlePubMedGoogle Scholar
- Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K: The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006, 63: 601–615. 10.1007/s00018-005-5426-3PubMed CentralView ArticlePubMedGoogle Scholar
- Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91: 3527–3561.PubMedGoogle Scholar
- Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Esser N: The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 2004, 7: 347–354. 10.1007/s10456-005-1394-3View ArticlePubMedGoogle Scholar
- Fayette J, Soria JC: Use of angiogenesis inhibitors in tumor treatment. Eur J Cancer 2005, 41: 1109–1116. 10.1016/j.ejca.2005.02.017View ArticlePubMedGoogle Scholar
- Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001, 280: C1358-C1366.PubMedGoogle Scholar
- Ferrara N: VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002, 2: 795–803. 10.1038/nrc909View ArticlePubMedGoogle Scholar
- Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25: 581. 10.1210/er.2003-0027View ArticlePubMedGoogle Scholar
- Ferrara N, Gerber HP, LeCourter J: The biology of VEGF and its receptors. Nat Med 2003, 9: 669–676. 10.1038/nm0603-669View ArticlePubMedGoogle Scholar
- Ferrara N, Hillan KJ, Novotny W: Bevacizumab (avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005, 333: 328–335. 10.1016/j.bbrc.2005.05.132View ArticlePubMedGoogle Scholar
- Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1: 27–31. 10.1038/nm0195-27View ArticlePubMedGoogle Scholar
- Frumovitz M, Sood AK: Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynaecologic malignancies. Gynecol Oncol 2007, 104: 768–778. 10.1016/j.ygyno.2006.10.062PubMed CentralView ArticlePubMedGoogle Scholar
- Garner A: Vascular diseases. In Pathobiology of ocular disease. A dynamic approach. 2nd edition. Edited by: Garner A, Klintworth GK. New York: Marcel Dekker; 1994:1625–1710.Google Scholar
- Grosdidier A, Zoete V, Michielin O: EADock: docking of small molecules into protein active sites with a multiobjective evolutionary optimization. Proteins 2007, 67: 1010–1025. 10.1002/prot.21367View ArticlePubMedGoogle Scholar
- Grosdidier A, Zoete V, Michielin O: SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 2011, 39: W270-W277. 10.1093/nar/gkr366PubMed CentralView ArticlePubMedGoogle Scholar
- Grosdidier A, Zoete V, Michielin O: Fast docking using the CHARMM force field with EADock DSS. J Comput Chem 2011, 32: 2149–2159. 10.1002/jcc.21797View ArticlePubMedGoogle Scholar
- Haberfeld H (Ed): Austria-codex (in German) (2009/2010 edn). Vienna: Österreichischer Apothekerverlag; 2009.Google Scholar
- Halgren TA: Merck molecular force field. I. Basis, form, scope, parametrization, and performance of MMFF94. J Comput Chem 1996, 17: 490–519. 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-PView ArticleGoogle Scholar
- Halgren TA: Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J Comput Chem 1996, 17: 520–552. 10.1002/(SICI)1096-987X(199604)17:5/6<520::AID-JCC2>3.0.CO;2-WView ArticleGoogle Scholar
- Halgren TA: Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. J Comput Chem 1996, 17: 553–586. 10.1002/(SICI)1096-987X(199604)17:5/6<553::AID-JCC3>3.0.CO;2-TView ArticleGoogle Scholar
- Halgren TA: Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J Comput Chem 1996, 17: 616–641. 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-XView ArticleGoogle Scholar
- Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG: ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 2012, 52: 1757–1768. 10.1021/ci3001277PubMed CentralView ArticlePubMedGoogle Scholar
- Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307: 58–62. 10.1126/science.1104819View ArticlePubMedGoogle Scholar
- Kluetz PG, Figg WD, Pharm D, Dahut WL: Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacotherapy 2010, 11: 233–247. 10.1517/14656560903451716View ArticleGoogle Scholar
- Lee K, Jeong K, Lee Y, Song JY, Kim MS, Lee GS, Kim Y: Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur J Med Chem 2010, 45: 5420–5427. 10.1016/j.ejmech.2010.09.002View ArticlePubMedGoogle Scholar
- Martinez JD, Parker MT, Fultz KE, Ignatenko NA, Gerner EW: Molecular biology of cancer. Chemotherapeutic agents. In Burger’s Medicinal chemistry and drug discovery. 6th edition. Edited by: Abraham DJ. Hoboken, NJ: John Wiley & Son Inc; 2003:1–50.Google Scholar
- McDonald IK, Thornton JM: Satisfying hydrogen bonding potential in proteins. J Mol Biol 1994, 238: 777–793. 10.1006/jmbi.1994.1334View ArticlePubMedGoogle Scholar
- Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996, 56: 1615–1620.PubMedGoogle Scholar
- Morabito A, Maio ED: Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006, 11: 753–764. 10.1634/theoncologist.11-7-753View ArticlePubMedGoogle Scholar
- Moreira IS, Fernandes PA, Ramos MJ: Vascular endothelial growth factor (VEGF) inhibition–a critical review. Anticancer Agents Med Chem 2007, 7: 223–245. 10.2174/187152007780058687View ArticlePubMedGoogle Scholar
- Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998, 19: 1639–1662. 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-BView ArticleGoogle Scholar
- Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signaling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7: 356–371.View ArticleGoogle Scholar
- Otrock ZK, Makarem JA, Shamseddine AI: Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007, 38: 258–268. 10.1016/j.bcmd.2006.12.003View ArticlePubMedGoogle Scholar
- Petrova TV, Makinen T, Alitalo K: Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999, 253: 117–130. 10.1006/excr.1999.4707View ArticlePubMedGoogle Scholar
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE: UCSF chimera–a visualization system for exploratory research and analysis. J Comput Chem 2004, 25: 1605–1612. 10.1002/jcc.20084View ArticlePubMedGoogle Scholar
- Roskoski R Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007, 62: 179–213. 10.1016/j.critrevonc.2007.01.006View ArticlePubMedGoogle Scholar
- Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C: CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 2003, 63: 5978–5991.PubMedGoogle Scholar
- Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219: 983–985. 10.1126/science.6823562View ArticlePubMedGoogle Scholar
- Solis FJ, Wets RJB: Minimization by random search techniques. Math Oper Res 1981, 6: 19–30. 10.1287/moor.6.1.19View ArticleGoogle Scholar
- Sood AK, Coleman RL, Ellis LM: Beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol 2011, 30: 345–347.View ArticlePubMedGoogle Scholar
- Terman BI, Stoletov KV: VEGF and tumor angiogenesis. Einstein Quart J Biol and Med 2001, 18: 59–66.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.